Search Within

Barbara Ann Macgregor-Cortelli

Formats
  1. Meeting Abstract (9)
  2. Journal Article (7)
Groups
  1. Nursing (16)
  2. Department of Medicine (15)
  3. Hematologic Malignancies, Division of (14)
  4. Center for Hematologic Malignancies (11)
  5. Lymphoma (11)
  6. Body Imaging Service (5)

More Groups

People
  1. Owen O'connor (15)
  2. Craig Moskowitz (11)
  3. Andrew Zelenetz (10)
  4. David Straus (9)
  5. Paul Hamlin (6)
  6. Carol Portlock (5)

More People

Years
  1. 2007 (2)
  2. 2006 (3)
  3. 2005 (3)
  4. 2004 (3)
  5. 2003 (3)
  6. 2002 (2)
Publications
  1. Blood (6)
  2. British Journal of Haematology (2)
  3. Journal of Clinical Oncology (2)
  4. Clinical Cancer Research (1)
  5. Clinical Oncology (1)
  6. EJC Supplements (1)

More Publications

Publishers
  1. American Society of Hematology (6)
  2. American Association for Cancer Research (2)
  3. American Society of Clinical Oncology (2)
  4. John Wiley & Sons (2)
  5. Elsevier Science, Inc. (1)
  6. Harborside Press (1)

More Publishers

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II
    Journal Article

    O'connor, O.; Wright, J.; Moskowitz, C. H.; Muzzy, J.; Macgregor-Cortelli, B.; Hamlin, P.; Straus, D.; Trehu, E.; Schenkein, D. P.; Zelenetz, A. D.
    Journal of the National Comprehensive Cancer Network (2004)

    Fulltext@MSK | Save
  • Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas
    Meeting Abstract

    O'Connor, O. A.; Wright, J.; Moskowitz, C.; Straus, D.; Macgregor-Cortelli, B.; Muzzy, J.; Choi, P.; Schenkein, D.; Zelenetz, A. D.
    EJC Supplements (2003)

    Fulltext@MSK | Save
  • Promising activity of the proteasome inhibitor bortezomib (velcade) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    Meeting Abstract

    O'connor, O.; Wright, J.; Moskowitz, C. H.; Muzzy, J.; Macgregor-Cortelli, B.; Hamlin, P.; Straus, D.; Trehu, E.; Schenkein, D. P.; Zelenetz, A. D.
    Blood (2003)

    Fulltext@MSK | Save
  • Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously
    Journal Article

    Kelly, Wm K.; Richon, V. M.; O'connor, O.; Curley, T.; Macgregor-Cortelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; more...
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Phase II clinical experience with the proteasome inhibitor PS-341 in patients with indolent lymphomas
    Meeting Abstract

    O'Connor, O. A.; Moskowitz, C. H.; Wright, J. J.; Macgregor-Cortelli, B.; Straus, D.; Furst, D.; Horse-Grant, D.; Schenkein, D. P.; Zelenetz, A. D.
    Blood (2002)

    Fulltext@MSK | Save
  • Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)
    Meeting Abstract

    O'Connor, O. A.; Richon, V.; Moskowitz, C. H.; Zelenetz, A. D.; Macgregor-Cortelli, B.; Curly, T.; Richardson, S.; Tong, W.; Rifkind, R.; Marks, P.; more...
    Blood (2002)

    Fulltext@MSK | Save